ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

CUSIP: 82835W108

Q1 2026 13F Holders as of 31 Mar 2026

Security identity
Security type / class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
99,255,583
Holder snapshot
Total 13F shares
93,317,906
Share change
+4,506,361
Total reported value
$749,531,191
Put/Call ratio
29%
Reported price per share
$8.03
Number of holders
198
Value change
+$15,625,071
Number of buys
91
Number of sells
80

Security key

82835W108

Report period

Q1 2026

Institutions

198

Top holders

10

SPRY full security history Ownership snapshot Full 13F holder table Previous quarter: Q4 2025 ARS Pharmaceuticals, Inc. SEC filings ARS Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
RA CAPITAL MANAGEMENT, L.P.
13D/G signal
RA CAPITAL MANAGEMENT, L.P.
Evidence rows
15
Latest as of
27 Mar 2026
13F 13D/G 3/4/5 Lead comparable stake: 11% 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-6 of 15 holder rows.
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G 3/4/5
Company · Director, 10%+ Owner
13F 13D/G 3/4/5
11%
from 13D/G
$126,530,382
10,860,977 shares
 — 31 Dec 2025
Rubric Capital Management LP
13F 13D/G
Company
13F 13D/G
8.1%
from 13D/G
$72,230,000
6,200,000 shares
 — 31 Dec 2025
James E. Flynn
3/4/5 13D/G
10%+ Owner · Deerfield Management Company, L.P.
3/4/5 13D/G
7.8%
from 13D/G
$180,437,416
9,774,508 shares
 -$13,663,151 27 Jun 2025
MILLENNIUM MANAGEMENT LLC
13D/G 13F
Company
13D/G 13F
6%
$48,748,087
5,916,030 shares
 +$4,322,622 27 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5%
from 13D/G
$59,243,944
5,085,317 shares
 — 31 Dec 2025
ORBIMED ADVISORS LLC
13F
Company
13F
8.4%
$96,561,142
8,288,510 shares
 — 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
198
Shares
93,317,906
Rows available
198
Investor Option Weight % Change % Reported value * Price Shares Share Change Activity Report Period

* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
189
Q1 2026 holders
198
Holder diff
9
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .